Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.
The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or in combination with either anti-CTLA-4 (ipilimumab...
Protein identified as potential druggable target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC),...
Minority colorectal cancer patients report higher burden of poor quality-of-life than whites
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics...
Study provides path for new immunotherapy approaches to prostate cancer
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Based on their findings, the researchers launched a clinical trial for stage IV prostate cancer in March combining two drugs that target separate...
Jerry Jeff Walker to headline April 29 Polo on the Prairie in West Texas
The 31st annual Polo on the Prairie, a U.S. Polo Association-sanctioned event benefiting cancer research and patient care programs at The...
MD Anderson expert to lead Dallas panels on Alzheimer’s disease
The University of Texas MD Anderson Cancer Center brings Jim Ray, Ph.D., head of Neuroscience, to Dallas on Thursday, April 20, to lead two...
Marshall E. Hicks named interim president of UT MD Anderson Cancer Center
University of Texas System Chancellor William H. McRaven announced today the appointment of Marshall E. Hicks, M.D., as interim president...
Advanced form of proton therapy shows promise for treating lung cancer recurrence
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment...
MD Anderson celebrates the mission of Kick Butts Day
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
Change in Leadership at MD Anderson
Ronald A. DePinho M.D., president of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven...
Statement from The University of Texas System Chancellor William H. McRaven
When Dr. Ron DePinho was named president of The University of Texas MD Anderson Cancer Center by the Board of Regents in 2011, ...
Functional brain training alleviates chemotherapy-induced peripheral nerve damage in cancer survivors
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
MD Anderson to provide skin cancer screenings, cancer prevention education at Shell Houston Open
Cancer prevention specialists from The University of Texas MD Anderson Cancer Center will provide skin cancer screenings free to the public...
Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
Absent tumor-suppressors allow melanoma to thwart immunotherapy
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint...
MD Anderson study ties protein ‘reader’ ENL to common leukemia
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid...